The US Food and Drug Administration (FDA) sanctioned Dupixent for children 1-11 with a specific oesophagus allergy, provided they weigh over 15 kg.
Regeneron and Sanofi developed this treatment, previously authorized in 2022, for patients 12 and older with eosinophilic esophagitis (EoE). EoE is an immune disorder involving damaging eosinophil accumulation in the oesophagus.
EoE condition affects about 21,000 U.S. children under 12, with nearly 9,000 not responding well to existing treatments. Dupixent’s price is $3,803.20 per carton, but most patients won’t pay this amount.
The drug, also treating eczema and asthma, earned $8.68 billion globally in 2022. Its recent approval followed successful trials in younger EoE patients.
Additionally, Dupixent might soon be authorized for chronic obstructive pulmonary disease (COPD), affecting 16 million Americans. However, the FDA previously rejected its use for chronic spontaneous urticaria, a skin condition.
 in children aged 1-11. Learn how this groundbreaking decision offers new hope for young patients suffering from this allergic inflammation of the esophagus.){kind=link}